Sun Pharmaceutical Industries gains on launching LEQSELVI in U.S.
Sun Pharmaceutical Industries is currently trading at Rs 1698.85, up by 16.80 points or 1.00% from its previous closing of Rs 1682.05 on the BSE.
The scrip opened at Rs 1700.00 and has touched a high and low of Rs 1710.85 and Rs 1688.85 respectively. So far 58184 shares were traded on the counter.
The BSE group 'A' stock of face value Rs 1 has touched a 52-week high of Rs 1960.20 on 30-Sep-2024 and a 52-week low of Rs 1555.00 on 05-Mar-2025.
Last one week high and low of the scrip stood at Rs 1710.85 and Rs 1646.95 respectively. The current market cap of the company is Rs 407119.16 crore.
The promoters holding in the company stood at 54.48%, while Institutions and Non-Institutions held 36.66% and 8.87% respectively.
Sun Pharmaceutical Industries has launched LEQSELVI (deuruxolitinib) 8 mg tablets in the United States. LEQSELVI (deuruxolitinib) 8 mg tablets is now available to healthcare providers and people living with severe alopecia areata in the U.S. LEQSELVI is indicated for the treatment of adults with severe alopecia areata.
With limited treatment options available to people living with severe alopecia areata in the U.S., the need for innovative therapies such as LEQSELVI remains critically important. LEQSELVI demonstrated rapid results in clinical trials with one third of patients regaining almost all of their hair by Week 24. Some patients (3%) achieved 80% or more scalp coverage as fast as 8 weeks.
Sun Pharmaceutical Industries (Sun Pharma) is the world's fourth largest specialty generic pharmaceutical company and India's top pharmaceutical company.
